doi:

DOI: 10.3724/SP.J.1264.2011.00021

Chinese Journal of Multiple Organ Diseases in the Elderly (中华老年多器官疾病杂志) 2011/10:4 PP.374-376

Leflunomide and rheumatoid interstitial lung disease


Abstract:
Interstitial lung disease(ILD) is one of the common extra-articular manifestations of rheumatoid arthritis(RA). Its incidence in RA is 7.7%, and the prognosis is poor. Leflunomide is one of the commonly used drugs for RA, but there are more and more reports about leflunomide caused interstitial pneumonia. Then, should leflunomide be used when RA is complicated with ILD? However, It has been reported that leflunomide can be an effective treatment for RA patient who already sufferred from lung disease [including ILD caused by methotrexate (MTX)], and no adverse drug reaction or pulmonary exacerbation was observed. So, leflunomide could be used as a replacement therapy in patients with MTX related ILD. The safety of leflunomide in treatment of RA was relatively approved in China, but the reports on leflunomide induced ILD were not rare recently outside of China. A cohort study performed in Canada reported that the risk of ILD was increased in RA patients treated with leflunomide (adjusted RR 1.9), but it was not elevated in patients with no previous history of MTX use or ILD(adjusted RR1.2). Japanese scholars proposed that leflunomide application should be prohibited or require careful consideration in elderly male RA patients with history of ILD or smoking. Pulmonary function responsed to leflunomide adversely in an ethnic group dependent manner. Genetics testing might be the key to find the answer. Although leflunomide had a potential risk of causing ILD, meta-analysis indicated satisfactory therapeutic effects and safety of leflunomide for RA. For RA patients with preexisting pulmonary disorders, leflunomide application requires careful consdideration and CT scanning should be monitored regularly.

Key words:leflunomide,arthritis, rheumatoid,lung disease, interstitial

ReleaseDate:2014-07-21 15:56:26



[1] Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheu-matoid arthritis: a population-based study[J]. Arthritis Rheum, 2010, 62(6): 1583-1591.

[2] 李国强, 魏路清. 类风湿关节炎间质性肺疾病的研究进展[J]. 临床内科杂志, 2008, 25(1): 70-71.

[3] Bilgici A, Ulusoy H, Kuru O, et al. Pulmonary involvement in rheumatoid arthritis[J]. Rheumatol Int, 2005, 25(6): 429- 435.

[4] 韩淑玲, 金京玉, 王宽婷, 等. 类风湿关节炎并发肺间质纤维化(附25例报告)[J]. 北京医学, 2006, 26(10): 593-595.

[5] Brown KK. Rheumatoid lung diease[J]. Proc Am Thorac Soc, 2007, 4 (5): 443 - 448.

[6] Ayhan-Ardic FF,Oken O, Yorgancioglu ZR, et al. Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms[J]. Clin Rheumatol, 2006, 25(2): 213- 218.

[7] Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis[J]. Rheumatology(Oxford), 2006, 45(7): 787-789.

[8] 黄建林, 古洁若, 李明明, 等. 来氟米特治疗类风湿关节炎的随机双盲对照多中心临床研究[J]. 中国新药与临床杂志, 2010, 29(1): 30-34.

[9] 姜林娣, 陈慧勇, 於 强, 等. 国产来氟米特治疗类风湿关节炎的随机双盲对照试验[J]. 中国循证医学杂志, 2005, 5(10): 743-746,785.

[10] 王 华, 张书锋. 来氟米特致呼吸系统不良反应2例[J].实用儿科临床杂志, 2007, 12(17): 1298.

[11] 陈 琳, 张恩娟, 张 笛, 等. 来氟米特致间质性肺炎继发死亡1例[J]. 药事管理, 2009, 6(4): 252-256

[12] Chikura B, Lane S, Dawson JK. Clinical expression of le-flunomide-induced pneumonitis[J]. Rheumatology(Oxford), 2009, 48(9): 1065–1068.

[13] Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis[J]. Arthritis Rheum., 2006, 54(5): 1435-1439.

[14] Hirabayashi Y, Shimizu H, Kobayashi N, et al. Leflunomide- induced pneumonitis in a patient with rheu-matoid arthritis[J]. Intern Med, 2006, 45(10): 689-691.

[15] 黄 烽. 从日本Arava事件看药物不良反应监测的重要性[J]. 中国药物应用与监测, 2004, 1(1): 1-3.

[16] Sato T, Inokuma S, Sagawa A, et al. Factors associ-ated with fatal outcome of leflunomide-inducedlung injury in Japanese patients with rheumatoid arthritis[J]. Rheumatol-ogy(Oxford), 2009, 48(10): 1265-1268.

[17] Inokuma S, Sato T, Sagawa A, et al. Proposals for leflunomide use to avoid lung injury in patients with rheu-matoid arthritis[J]. Mod Rheumatol, 2008, 18(15): 442- 446.

[18] Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Ko-rean patients with rheumatoid arthritis[J]. Arthritis Rheum, 2007, 56(6): 2094-2096.

[19] Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances[J]. Curr Opin Pulm Med, 2006, 12(5): 346- 353

[20] Wong SP, Chu CM, Kan CH, et al. Successful treatment of leflunomide -induced acute pneumonitis with cholestyramine wash-out therapy[J]. J Clin Rheumatol, 2009, 15(8): 389- 392.

[21] Nandi P, Kingsley GH, Scott DL. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid ar-thritis and seronegative arthritis[J]. Curr Opin Rheumatol, 2008, 20(3): 251-256.

[22] Lee SS, Park YW, Park JJ, et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis[J]. Scand J Rheumatol., 2009, 38(1): 11-14.

[23] Kelly C, Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease[J]. Expert Opin Pharmacother, 2008, 9 (18): 3221-3230.

PDF